A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Neoplasm Metastasis
Interventions: DRUG: CP-724,714
Sponsor: Pfizer